Sign up
Pharma Capital
EPIC: ATE
Market: TSX-V:ATE
OTCMKTS:ATBPF
52-week High/Low: C$0.39 / C$0.24
Sector: Pharma & Biotech
Market Cap: C$76.67M
Website: antibethera.com

Antibe Therapeutics is a publicly-traded biotechnology company pursuing a breakthrough advance in the treatment and prevention of inflammation. Antibe's drug pipeline addresses a $20+ billion market in non-addictive pain management, cardiovascular disease, and cancer prevention. Antibe’s lead drug, now in late Phase 2 trials, is demonstrating unprecedented safety and efficacy in the...

Antibe Therapeutics

antibethera.com

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Antibe Therapeutics

Antibe Therapeutics Snapshot

Antibe Therapeutics is pursuing a major advance in the safe and non-addictive treatment of pain and inflammation. Our drugs are designed to prevent the widespread and serious gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs (“NSAIDs”), today’s most widely used medicines for the relief of pain. The NSAID class of drugs includes prescription and over-the-counter (“OTC”) brands such as naproxen (Aleve), celecoxib (Celebrex), ibuprofen (Advil), and Aspirin.

Daniel Legault - Chief Executive Officer & Director
Dan is an entrepreneur and executive with extensive experience in guiding early stage businesses. As a founder, CEO, and turnaround specialist, he has managed entrepreneurial organizations through key transitions – and recoveries – in the commercial and charitable sectors. In addition to pharmaceuticals, Dan has substantial experience in information technology, marketing analytics, intellectual property governance, and risk management. Dan served as a board member of Green Shield Canada (GSC) for 17 years, one of Canada’s largest health benefits administrators. He is a member of the Law Society of Upper Canada and the New York Bar, and earned his JD at Queen’s University.

Alain Wilson - Chief Financial Officer
Alain is a management consultant with extensive experience in strategy and financial analysis in a variety of industries. Over the last 30 years Alain has worked with senior executives on key strategic issues both in North America and internationally. He was a Vice President and Toronto Office Head for Mercer Management Consulting (now Oliver Wyman), and more recently a founding partner of Revelstoke Partners, a boutique consulting firm focused on assisting mid-market companies. Alain has a Bachelor of Commerce (Honours) from Queen’s University and an MBA from IMD in Switzerland.

John Wallace - Chief Scientific Officer & Director
John is an Adjunct Professor of Physiology & Pharmacology at the Cumming School of Medicine at the University of Calgary. He holds a PhD in Medical Sciences (University of Toronto), a B.Sc. and an M.Sc. in Biological Sciences (Queen’s University). From 2009 to 2012, John was Founding Director of the Farncombe Family Digestive Health Research Institute at McMaster University. He completed post-doctoral studies at the Wellcome Research Laboratories in London, England, and he holds an MBA from the University of Birmingham, England.

David Vaughan - Chief Development Officer
Dave has over 20 years of experience in the pharmaceutical industry as a drug development consultant providing support for preclinical, clinical, regulatory, business development and marketing functions in the anti-infectives, central nervous system and GI disease areas. He is the former head of the anti-infectives product development unit for Bayer Inc. Dave holds a PhD in Clinical Biochemistry from the University of Toronto.

Scott Curtis - Corporate Development
Scott has 6 years of capital markets experience including 3 years as an investment banking professional at Bloom Burton & Co., a leading healthcare-focused investment dealer and advisory firm in Canada. He was most recently Vice President & Research Analyst at Cantor Fitzgerald Canada where he covered a variety of sectors including Specialty Pharma. Scott holds a Bachelor of Biomedical Computing from Queen’s University, a Master of Computer Engineering from the University of Toronto and is a CFA charterholder.

BOARD OF DIRECTORS

Walt Macnee - Chair of the Board

Walt is the Vice Chairman of MasterCard Inc., where he oversees senior client, government and merchant relationships and plays a central role in steering the company strategy toward the wider merchant community and other key stakeholders. Previously, Walt served as President, International Markets, of MasterCard Worldwide. Walt holds Bachelor degrees in Arts and in Education from Queen’s University and an MBA from York University.

Roderick Flower
Rod is an Emeritus Professor of Pharmacology at the William Harvey Research Institute (WHRI) at Queen Mary University of London. He is a Fellow of the Royal Society of London and the Academy of Medical Sciences. He holds a B.Sc. from the University of Sheffield, a PhD and a D.Sc. from the University of London and an honorary LL.D. from the University of Bath.

Amal Khouri
Amal has more than 15 years of business development experience in the pharmaceutical industry and is presently Vice President of Business Development at Knight Therapeutics Inc. (“Knight”). Prior to Knight, Ms. Khouri worked at Novartis Pharma for over 7 years, where she held multiple positions within the global business development and licensing team in Basel, Switzerland. Before joining Novartis, she worked in business development at Paladin Labs in roles with increasing responsibilities. Ms. Khouri holds a B.Sc. in Biochemistry from McGill University and an M.B.A. from the University of Ottawa.

Daniel Legault
Dan is an entrepreneur and executive with extensive experience in guiding early stage businesses. He has served as CEO of Antibe since its formation in May 2009. Dan served as a director and audit committee member of Green Shield Canada for 17 years, one of the country’s largest health benefits administrators. He is a member of the Law Society of Upper Canada and the New York Bar and holds a JD from Queen’s University.

John Wallace
John is an Adjunct Professor of Physiology & Pharmacology at the Cumming School of Medicine at the University of Calgary. He holds a PhD in Medical Sciences (University of Toronto), a B.Sc. and an M.Sc. in Biological Sciences (Queen’s University). From 2009 to 2012, John was Founding Director of the Farncombe Family Digestive Health Research Institute at McMaster University. He completed post-doctoral studies at the Wellcome Research Laboratories in London, England, and he holds an MBA from the University of Birmingham, England.

Yung Wu
Yung is a serial founder and entrepreneur, technology innovator, private equity investor and Corporate Director. He has created, led, financed and directed companies spanning enterprise software, mobile technology, entertainment & media, financial services and oil & gas exploration. Yung has been recognized as one of Canada’s ‘Top 40 under 40’ leaders and for leading one of the “50 Best Managed Private Companies” in the nation. He has a bachelor’s degree in Computer Science, Economics and Mathematics from the University of Toronto, a graduate of the Entrepreneurial Masters Program at the Massachusetts Institute of Technology, a member of MENSA, the Young Presidents Organization (YPO) and the Institute of Corporate Directors (ICD.D). Yung is currently Chief Executive Officer of MaRS Discovery District.

Head Office
Antibe Therapeutics Inc.
15 Prince Arthur Avenue
Toronto, Ontario, Canada
M5R 1B2
[email protected]

Investor Relations
Christina Cameron
VP, Investor Relations
[email protected]

View full ATE profile View Profile
View All

Market Reports Including ATE

VIEW ALL

Executive video interviews

VIEW ALL VIDEOS

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.